mp.weixin.qq.com·· 5 hours agoPickScore85
Ivonescimab posts 14.9-month overall survival in HARMONi-GI1 head-to-head biliary tract cancer trial
In brief
Ivonescimab achieved a median overall survival of 14.9 months in the Phase III HARMONi-GI1 head-to-head study in biliary tract cancer, with a statistically significant positive OS result. It is the first global Phase III study in biliary tract cancer to show significant OS benefit against a PD-L1 antibody plus chemotherapy control; the TOPAZ-1 study previously established durvalumab plus gemcitabine and cisplatin as first-line standard of care.
Why it matters
First global Phase III head-to-head OS-positive result in biliary tract cancer against a PD-L1 antibody plus chemotherapy control, providing direct data against the existing standard regimen.
Source: mp.weixin.qq.com · mp.weixin.qq.com